Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardonilimab in Advanced Melanoma and Renal Cancer
NCT06670300Phase 2Not yet recruiting
- Sponsor
- Protgen
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in mucosal melanoma (MM), acral lentiginous melanoma (ALM) and renal cell carcinoma (RCC) (2 arms), sponsored by Protgen. Primary endpoint: Objective Response Rate up to 24 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
mucosal melanoma (MM)acral lentiginous melanoma (ALM)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06670300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06670300.